検索
Roivant Sciences Ltd
ROIVウォッチリストに追加
31.485USD
+0.055+0.17%
取引時間 （ET）15分遅れの株価
22.34B時価総額
損失額直近12ヶ月PER
詳細情報 Roivant Sciences Ltd 企業名
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltdの企業情報
企業コードROIV
会社名Roivant Sciences Ltd
上場日Dec 03, 2020
最高経営責任者「CEO」Venker (Eric)
従業員数750
証券種類Ordinary Share
決算期末Dec 03
本社所在地7Th Floor, 50 Broadway
都市LONDON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United Kingdom
郵便番号SW1H 0DB
電話番号4412955950
ウェブサイトhttp://roivant.com/
企業コードROIV
上場日Dec 03, 2020
最高経営責任者「CEO」Venker (Eric)
Roivant Sciences Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.58M
-1.18%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.75%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
-2.36%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
113.36K
+13.79%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
101.64K
+0.79%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.00K
+0.40%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
76.72K
-24.71%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
68.00
-60575.00%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-100.00%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.58M
-1.18%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.75%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
-2.36%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
113.36K
+13.79%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
101.64K
+0.79%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.00K
+0.40%
よくある質問
Roivant Sciences Ltdの上位5名の株主は誰ですか？
Roivant Sciences Ltdの上位5名の株主は以下のとおりです。Dr. Frank M. Torti, M.D.
Roivant Sciences Ltd（ROIV）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Roivant Sciences Ltdの株式を保有している機関は781社あり、保有株式の総市場価値は約565.52Mで、全体の79.01%を占めています。2025Q4と比較して、機関の持ち株は-23023750.00増加しています。
